The objective of this retrospective real-world observational study was to compare 6-month (mo) adherence and persistence among patients (pts) initiating weekly GLP-1 receptor agonists (GLP-1RA), dulaglutide (DU) vs. semaglutide (SEMA) or DU vs. exenatide QW (EQW) BCise pen in the U.S., using claims from the HealthCore Integrated Research Database (HIRD®) between August 2017 and June 2019 (index date=earliest GLP-1RA fill date). Pts ≥18 yrs old, with T2D, no claim for GLP-1 RAs in the 6 mos pre-index period, ≥1 claim for DU, SEMA or EQW during the index period, and continuous enrollment 6 mos pre- and post-index were included. DU users were propensity-matched 1:1 to SEMA (3,852 pairs) or EQW (1,879 pairs) users. Matched cohorts (DU:SEMA/DU:EQW) were balanced in baseline characteristics and the mean age was 54/55 years with approximately 49/51% males, respectively. At 6 mos, DU users were more likely to be adherent [Proportion of Days Covered (PDC)≥80%] than SEMA (odds ratio [OR]=1.986, 95% CI=[1.81, 2.18]) or EQW users (2.06 [1.81, 2.34]) (table). Cox regression showed that DU users were less likely to discontinue therapy than SEMA (hazard ratio [HR]= 0.71, 95% CI=[0.66, 0.76]) or EQW users (0.59 [0.53, 0.65]) (table). At 6-mos follow-up, pts initiating DU had higher medication adherence, and were more persistent to their treatment, compared to pts initiating either SEMA or EQW.
R. Mody: Employee; Self; Eli Lilly and Company. M. Yu: Employee; Self; Eli Lilly and Company. Employee; Spouse/Partner; LifeLabs. Stock/Shareholder; Self; Eli Lilly and Company. B.K. Nepal: None. M. Konig: Employee; Self; Eli Lilly and Company. M. Grabner: Research Support; Self; Eli Lilly and Company.